137 related articles for article (PubMed ID: 38867314)
1. Bidirectional modulation of TCA cycle metabolites and anaplerosis by metformin and its combination with SGLT2i.
Harada M; Adam J; Covic M; Ge J; Brandmaier S; Muschet C; Huang J; Han S; Rommel M; Rotter M; Heier M; Mohney RP; Krumsiek J; Kastenmüller G; Rathmann W; Zou Z; Zukunft S; Scheerer MF; Neschen S; Adamski J; Gieger C; Peters A; Ankerst DP; Meitinger T; Alderete TL; de Angelis MH; Suhre K; Wang-Sattler R
Cardiovasc Diabetol; 2024 Jun; 23(1):199. PubMed ID: 38867314
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db/db mice.
Harada M; Han S; Shi M; Ge J; Yu S; Adam J; Adamski J; Scheerer MF; Neschen S; de Angelis MH; Wang-Sattler R
Int J Biol Macromol; 2024 Apr; 265(Pt 1):130962. PubMed ID: 38503370
[TBL] [Abstract][Full Text] [Related]
3. Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice.
Neschen S; Scheerer M; Seelig A; Huypens P; Schultheiss J; Wu M; Wurst W; Rathkolb B; Suhre K; Wolf E; Beckers J; Hrabé de Angelis M
Diabetes; 2015 Jan; 64(1):284-90. PubMed ID: 25071027
[TBL] [Abstract][Full Text] [Related]
4. The combination of exercise training and sodium-glucose cotransporter-2 inhibition improves glucose tolerance and exercise capacity in a rodent model of type 2 diabetes.
Linden MA; Ross TT; Beebe DA; Gorgoglione MF; Hamilton KL; Miller BF; Braun B; Esler WP
Metabolism; 2019 Aug; 97():68-80. PubMed ID: 31132381
[TBL] [Abstract][Full Text] [Related]
5. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
[TBL] [Abstract][Full Text] [Related]
6. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
Goldenberg RM
Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Euh W; Lim S; Kim JW
Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
[TBL] [Abstract][Full Text] [Related]
8. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
[TBL] [Abstract][Full Text] [Related]
9. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
Schechter M; Melzer-Cohen C; Rozenberg A; Yanuv I; Chodick G; Karasik A; Kosiborod M; Mosenzon O
Cardiovasc Diabetol; 2021 Aug; 20(1):169. PubMed ID: 34407822
[TBL] [Abstract][Full Text] [Related]
10. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
van Bommel EJM; Muskiet MHA; van Baar MJB; Tonneijck L; Smits MM; Emanuel AL; Bozovic A; Danser AHJ; Geurts F; Hoorn EJ; Touw DJ; Larsen EL; Poulsen HE; Kramer MHH; Nieuwdorp M; Joles JA; van Raalte DH
Kidney Int; 2020 Jan; 97(1):202-212. PubMed ID: 31791665
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk.
Kim JH; Lee M; Kim SH; Kim SR; Lee BW; Kang ES; Cha BS; Cho JW; Lee YH
Diabetes Obes Metab; 2019 Apr; 21(4):801-811. PubMed ID: 30407726
[TBL] [Abstract][Full Text] [Related]
12. Metformin Effect on Nontargeted Metabolite Profiles in Patients With Type 2 Diabetes and in Multiple Murine Tissues.
Adam J; Brandmaier S; Leonhardt J; Scheerer MF; Mohney RP; Xu T; Bi J; Rotter M; Troll M; Chi S; Heier M; Herder C; Rathmann W; Giani G; Adamski J; Illig T; Strauch K; Li Y; Gieger C; Peters A; Suhre K; Ankerst D; Meitinger T; Hrabĕ de Angelis M; Roden M; Neschen S; Kastenmüller G; Wang-Sattler R
Diabetes; 2016 Dec; 65(12):3776-3785. PubMed ID: 27621107
[TBL] [Abstract][Full Text] [Related]
13. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin.
McCormick N; Yokose C; Lu N; Wexler DJ; Aviña-Zubieta JA; De Vera MA; McCoy RG; Choi HK
JAMA Intern Med; 2024 Jun; 184(6):650-660. PubMed ID: 38619822
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
Chen TH; Li YR; Chen SW; Lin YS; Sun CC; Chen DY; Mao CT; Wu M; Chang CH; Chu PH; Wu VC
Cardiovasc Diabetol; 2020 Nov; 19(1):189. PubMed ID: 33167990
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.
D'Onofrio N; Sardu C; Trotta MC; Scisciola L; Turriziani F; Ferraraccio F; Panarese I; Petrella L; Fanelli M; Modugno P; Massetti M; Marfella LV; Sasso FC; Rizzo MR; Barbieri M; Furbatto F; Minicucci F; Mauro C; Federici M; Balestrieri ML; Paolisso G; Marfella R
Mol Metab; 2021 Dec; 54():101337. PubMed ID: 34500107
[TBL] [Abstract][Full Text] [Related]
16. The antidiabetic drug metformin decreases mitochondrial respiration and tricarboxylic acid cycle activity in cultured primary rat astrocytes.
Hohnholt MC; Blumrich EM; Waagepetersen HS; Dringen R
J Neurosci Res; 2017 Nov; 95(11):2307-2320. PubMed ID: 28316081
[TBL] [Abstract][Full Text] [Related]
17. Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?
Koufakis T; Papazafiropoulou A; Makrilakis K; Kotsa K
Cardiovasc Drugs Ther; 2023 Apr; 37(2):315-321. PubMed ID: 34476668
[TBL] [Abstract][Full Text] [Related]
18. Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
Koike M; Saito H; Kohno G; Takubo M; Watanabe K; Ishihara H
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768897
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
Tahara A; Takasu T
Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
[No Abstract] [Full Text] [Related]
20. Metabolic Communication by SGLT2 Inhibition.
Billing AM; Kim YC; Gullaksen S; Schrage B; Raabe J; Hutzfeldt A; Demir F; Kovalenko E; Lassé M; Dugourd A; Fallegger R; Klampe B; Jaegers J; Li Q; Kravtsova O; Crespo-Masip M; Palermo A; Fenton RA; Hoxha E; Blankenberg S; Kirchhof P; Huber TB; Laugesen E; Zeller T; Chrysopoulou M; Saez-Rodriguez J; Magnussen C; Eschenhagen T; Staruschenko A; Siuzdak G; Poulsen PL; Schwab C; Cuello F; Vallon V; Rinschen MM
Circulation; 2024 Mar; 149(11):860-884. PubMed ID: 38152989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
